NASDAQ:BDSX

Biodesix Competitors

$15.01
+0.77 (+5.41 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.80
$15.19
50-Day Range
$14.12
$22.25
52-Week Range
$10.85
$31.99
Volume127,449 shs
Average Volume97,410 shs
Market Capitalization$403.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Biodesix (NASDAQ:BDSX) Vs. HRTX, AMRX, REPL, PMVP, SUPN, and ADCT

Should you be buying BDSX stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Biodesix, including Heron Therapeutics (HRTX), Amneal Pharmaceuticals (AMRX), Replimune Group (REPL), PMV Pharmaceuticals (PMVP), Supernus Pharmaceuticals (SUPN), and ADC Therapeutics (ADCT).

Biodesix (NASDAQ:BDSX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Biodesix and Heron Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiodesixN/AN/AN/AN/AN/A
Heron Therapeutics$145.97 million11.03$-204,750,000.00($2.50)-7.02

Biodesix has higher earnings, but lower revenue than Heron Therapeutics.

Institutional & Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Biodesix and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiodesixN/AN/AN/A
Heron Therapeutics-216.18%-65.06%-49.14%

Analyst Ratings

This is a summary of recent recommendations and price targets for Biodesix and Heron Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biodesix00403.00
Heron Therapeutics01402.80

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Heron Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 48.06%. Given Biodesix's stronger consensus rating and higher possible upside, research analysts plainly believe Biodesix is more favorable than Heron Therapeutics.

Summary

Biodesix beats Heron Therapeutics on 5 of the 8 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Biodesix and Amneal Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiodesixN/AN/AN/AN/AN/A
Amneal Pharmaceuticals$1.63 billion0.98$-361,920,000.00$0.2719.67

Biodesix has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Institutional & Insider Ownership

33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Biodesix and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiodesixN/AN/AN/A
Amneal Pharmaceuticals3.30%42.02%3.82%

Analyst Ratings

This is a summary of recent recommendations and price targets for Biodesix and Amneal Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biodesix00403.00
Amneal Pharmaceuticals01502.83

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Amneal Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 31.83%. Given Biodesix's stronger consensus rating and higher possible upside, research analysts plainly believe Biodesix is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Biodesix on 7 of the 9 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Biodesix and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiodesixN/AN/AN/A
Replimune GroupN/A-30.23%-24.66%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Biodesix and Replimune Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biodesix00403.00
Replimune Group00903.00

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Replimune Group has a consensus price target of $56.00, suggesting a potential upside of 64.75%. Given Biodesix's higher possible upside, equities analysts clearly believe Biodesix is more favorable than Replimune Group.

Earnings and Valuation

This table compares Biodesix and Replimune Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiodesixN/AN/AN/AN/AN/A
Replimune GroupN/AN/A$-52,630,000.00($1.54)-22.07

Insider and Institutional Ownership

55.8% of Replimune Group shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PMV Pharmaceuticals (NASDAQ:PMVP) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for PMV Pharmaceuticals and Biodesix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PMV Pharmaceuticals01302.75
Biodesix00403.00

PMV Pharmaceuticals presently has a consensus target price of $38.00, suggesting a potential upside of 9.10%. Biodesix has a consensus target price of $26.00, suggesting a potential upside of 73.22%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than PMV Pharmaceuticals.

Earnings & Valuation

This table compares PMV Pharmaceuticals and Biodesix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/AN/AN/AN/A
BiodesixN/AN/AN/AN/AN/A

Profitability

This table compares PMV Pharmaceuticals and Biodesix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PMV PharmaceuticalsN/AN/AN/A
BiodesixN/AN/AN/A

Institutional and Insider Ownership

69.7% of PMV Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biodesix beats PMV Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Profitability

This table compares Supernus Pharmaceuticals and Biodesix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Supernus Pharmaceuticals27.09%20.02%9.67%
BiodesixN/AN/AN/A

Institutional and Insider Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Supernus Pharmaceuticals and Biodesix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Supernus Pharmaceuticals00203.00
Biodesix00403.00

Supernus Pharmaceuticals presently has a consensus price target of $37.50, suggesting a potential upside of 27.77%. Biodesix has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Given Biodesix's higher probable upside, analysts clearly believe Biodesix is more favorable than Supernus Pharmaceuticals.

Earnings and Valuation

This table compares Supernus Pharmaceuticals and Biodesix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$392.76 million3.96$113.06 million$2.1013.98
BiodesixN/AN/AN/AN/AN/A

Supernus Pharmaceuticals has higher revenue and earnings than Biodesix.

Summary

Supernus Pharmaceuticals beats Biodesix on 6 of the 8 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares ADC Therapeutics and Biodesix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
BiodesixN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ADC Therapeutics and Biodesix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
Biodesix00403.00

ADC Therapeutics currently has a consensus price target of $49.25, suggesting a potential upside of 119.08%. Biodesix has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Biodesix.

Institutional and Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADC Therapeutics and Biodesix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million661.83$-116,480,000.00($2.36)-9.53
BiodesixN/AN/AN/AN/AN/A

Biodesix has lower revenue, but higher earnings than ADC Therapeutics.

Summary

ADC Therapeutics beats Biodesix on 3 of the 4 factors compared between the two stocks.


Biodesix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.56+5.3%$1.61 billion$145.97 million-7.11Earnings Announcement
Upcoming Earnings
High Trading Volume
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.31+2.1%$1.59 billion$1.63 billion12.95Earnings Announcement
Analyst Upgrade
Gap Up
Replimune Group logo
REPL
Replimune Group
1.5$33.99+5.4%$1.58 billionN/A-19.20
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$34.83+0.5%$1.56 billionN/A0.00Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.35+0.1%$1.56 billion$392.76 million12.18Earnings Announcement
Analyst Revision
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.48+4.9%$1.55 billion$2.34 million-9.53Earnings Announcement
Analyst Report
BioAtla logo
BCAB
BioAtla
1.7$46.00+1.8%$1.55 billionN/A0.00Gap Down
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$38.62+7.3%$1.55 billionN/A-160.92
Immunovant logo
IMVT
Immunovant
1.6$15.69+6.8%$1.54 billionN/A-12.16Analyst Report
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$43.49+5.4%$1.53 billionN/A0.00
Addus HomeCare logo
ADUS
Addus HomeCare
1.7$96.30+1.0%$1.53 billion$648.79 million0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.00+0.8%$1.53 billion$35.23 million-14.52Earnings Announcement
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$26.80+3.4%$1.52 billionN/A0.00
U.S. Physical Therapy logo
USPH
U.S. Physical Therapy
1.6$118.18+0.8%$1.52 billion$481.97 million50.29Earnings Announcement
Dividend Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
uniQure logo
QURE
uniQure
1.7$32.25+0.9%$1.48 billion$7.28 million-8.55Earnings Announcement
Upcoming Earnings
Inogen logo
INGN
Inogen
1.4$65.35+1.9%$1.46 billion$361.94 million-726.03Earnings Announcement
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.17+3.6%$1.46 billion$102.43 million-16.95Earnings Announcement
Analyst Upgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$65.89+7.4%$1.46 billionN/A-44.52
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$33.83+1.3%$1.46 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$40.70+2.2%$1.44 billionN/A0.00Insider Selling
AlloVir logo
ALVR
AlloVir
1.5$22.03+8.3%$1.43 billionN/A0.00Earnings Announcement
Insider Selling
Analyst Revision
Lantheus logo
LNTH
Lantheus
1.9$21.24+3.4%$1.43 billion$347.34 million265.53Earnings Announcement
Analyst Upgrade
High Trading Volume
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.45+1.2%$1.41 billion$6.20 million-14.23Upcoming Earnings
Kronos Bio logo
KRON
Kronos Bio
1.7$25.06+2.5%$1.41 billionN/A0.00
Eargo logo
EAR
Eargo
1.4$36.67+12.5%$1.40 billionN/A0.00Upcoming Earnings
Pulmonx logo
LUNG
Pulmonx
1.4$39.33+8.2%$1.40 billion$32.60 million0.00High Trading Volume
Bionano Genomics logo
BNGO
Bionano Genomics
1.3$5.01+8.0%$1.40 billion$10.13 million-2.64Upcoming Earnings
Gap Up
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$6.67+2.7%$1.39 billion$4.11 million-4.90Analyst Report
News Coverage
Gap Up
Brookdale Senior Living logo
BKD
Brookdale Senior Living
1.2$7.57+3.3%$1.39 billion$4.06 billion42.06Earnings Announcement
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.41+3.1%$1.38 billion$236.54 million-52.14Earnings Announcement
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$54.78+10.1%$1.37 billion$51.87 million-322.22Analyst Upgrade
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$31.37+9.0%$1.37 billionN/A-10.56Earnings Announcement
Gap Up
Alphatec logo
ATEC
Alphatec
1.0$14.02+7.8%$1.36 billion$113.43 million-12.75Earnings Announcement
Translate Bio logo
TBIO
Translate Bio
1.6$18.00+7.9%$1.35 billion$7.80 million-16.82Analyst Report
Analyst Revision
Zymeworks logo
ZYME
Zymeworks
1.6$28.49+6.4%$1.32 billion$29.54 million-7.56Earnings Announcement
Analyst Revision
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.4$35.77+4.8%$1.31 billionN/A0.00Upcoming Earnings
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.51+12.6%$1.30 billion$82.27 million-15.88Earnings Announcement
News Coverage
Gap Down
Precigen logo
PGEN
Precigen
1.7$6.24+4.8%$1.29 billion$90.72 million-3.32Upcoming Earnings
Insider Selling
News Coverage
908 Devices logo
MASS
908 Devices
1.7$47.18+7.0%$1.29 billionN/A0.00Upcoming Earnings
Alector logo
ALEC
Alector
1.3$16.12+1.4%$1.29 billion$21.22 million-7.23Earnings Announcement
EWTX
Edgewise Therapeutics
1.8$26.95+8.5%$1.28 billionN/A0.00Gap Down
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.5$10.00+1.4%$1.28 billion$320,000.00-6.80Earnings Announcement
Gap Up
Mesa Laboratories logo
MLAB
Mesa Laboratories
1.5$248.80+1.0%$1.28 billion$117.69 million-355.43
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$19.19+2.9%$1.25 billion$73.41 million-4.06Analyst Revision
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$28.62+4.3%$1.25 billionN/A0.00
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$28.29+3.1%$1.24 billion$230,000.00-13.16Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Endo International logo
ENDP
Endo International
1.5$5.28+6.6%$1.23 billion$2.91 billion-7.76Earnings Announcement
Analyst Revision
PetIQ logo
PETQ
PetIQ
1.6$42.03+2.1%$1.22 billion$709.43 million-13.26Earnings Announcement
High Trading Volume
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.73+4.1%$1.22 billion$75.86 million-0.28
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$23.31+1.5%$1.21 billion$4.23 million-17.27Earnings Announcement
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.